Treatment regimen employed
| Regimen (evaluable patients) | Patients (n) |
|---|---|
| *Cyclophosphamide was given at 4 g/m2 either in one injection or in two daily successive injections of 2 g/m2 according to the centres; †granulocyte-colony stimulating factor (G-CSF) used either rHu G-CSF (Lenograstim†, Aventis and Chugai Pharma, France) or G-CSF (Filgrastim†, AMGEN). | |
| ATG, antithymocyte globulins; TLI, total lymphoid irradiation. | |
| Priming (n = 56) | |
| Cyclophosphamide*+G-CSF† | 47 |
| Cyclophosphamide* alone | 2 |
| G-CSF alone | 6 |
| Cyclophosphamide*+VP16+G-CSF† | 1 |
| PBSC selection (n = 55) | |
| No selection | 7 |
| CD34+ selection alone | 38 |
| CD34+ and other monoclonal antibody | 9 |
| CAMPATH 1 alone | 1 |
| Conditioning (n = 57) | |
| Cyclophosphamide 150–200 mg/kg | 35 |
| Cyclophosphamide 120 mg/kg+ATG+TLI | 1 |
| Cyclophosphamide 200 mg/kg+ATG | 12 |
| Cyclophosphamide 200 mg/kg+CAMPATH-1 | 3 |
| Cyclophosphamide 200 mg/kg+TLI | 1 |
| Other chemotherapy | 4 |
| Unknown | 1 |